Elizabeth Barrett - Jan 3, 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Executive Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 3, 2022
Transactions value $
-$429,757
Form type
4
Date filed
1/7/2022, 07:38 AM
Previous filing
Aug 3, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +106K +44.13% 345K Jan 3, 2022 Direct F1
transaction URGN Ordinary Shares Sale -$430K -47K -13.61% $9.15 298K Jan 4, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -106K -100% $0.00* 0 Jan 3, 2022 Ordinary Shares 106K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs vested on January 3, 2022.